Table 1 Analysis of NUCKS immunostaining in non malignant, non metastatic breast lesions
| Â | Fibroepithelial tumours (n=13) | Benign epithelial proliferations (n = 31) | Intraductal proliferative lesions (n = 38) | |||
|---|---|---|---|---|---|---|
Overall NUCKS Immuno- Reactivity | Fibroadenoma (n = 13) RR = ns | Adenosis (n = 20) RR = ns | Sclerosing adenosis (n = 11) R = ns | Usual ductal hyperplasia, UDH (n = 16), RR = 1.5 | Atypical ductal hyperplasia, ADH, (n = 6), RR = 4.0–5.0 | Ductal carcinomas in situ, DCIS (n = 16), RR = 8.0–11.0 |
Negative (0) | 13(100%) | 3 (15%) | 1 (9%) | 3 (19%) | Â | 1 (6%) |
+1 | Â | 10 (50%) | 6(55%) | 8 (50%) | 1 (17%) | 2 (12%) |
+2 | Â | 6 (30%) | 4(36%) | 4 (25%) | 2 (33%) | 6 (38%) |
+3 | Â | 1 (5%) | Â | 1 (6%) | 3 (50%) | 7 (44%) |
Low expression (0/+1) | 13 (100%) | 13 (65%) | 7 (64%) | 11 (69%) | 1 (17%) | 3 (18%) |
High expression (+2/+3) | Â | 7 (35%) | 4 (36%) | 5 (31%) | 5 (83%) | 13 (82%) |